Troy Wichterman Sells 4,151 Shares of BioLife Solutions, Inc. (NASDAQ:BLFS) Stock

BioLife Solutions, Inc. (NASDAQ:BLFS) CFO Troy Wichterman sold 4,151 shares of the business’s stock in a transaction dated Tuesday, March 11th. The stock was sold at an average price of $25.00, for a total transaction of $103,775.00. Following the sale, the chief financial officer now directly owns 116,809 shares of the company’s stock, valued at approximately $2,920,225. The trade was a 3.43 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Troy Wichterman also recently made the following trade(s):

• On Monday, March 3rd, Troy Wichterman sold 660 shares of BioLife Solutions stock. The shares were sold at an average price of $25.46, for a total value of $16,803.60.
• On Wednesday, February 12th, Troy Wichterman sold 159 shares of BioLife Solutions stock. The stock was sold at an average price of $26.54, for a total value of $4,219.86.
• On Monday, January 6th, Troy Wichterman sold 987 shares of BioLife Solutions stock. The shares were sold at an average price of $27.02, for a total value of $26,668.74.

BioLife Solutions Price Performance

BLFS opened at $25.00 on Friday. BioLife Solutions, Inc. has a fifty-two week low of $14.84 and a fifty-two week high of $29.55. The firm has a 50-day moving average of $26.62 and a 200 day moving average of $25.50. The company has a debt-to-equity ratio of 0.03, a quick ratio of 1.78 and a current ratio of 2.78. The firm has a market cap of $1.18 billion, a P/E ratio of -23.58 and a beta of 2.04.

BioLife Solutions (NASDAQ:BLFS) last released its earnings results on Monday, March 3rd. The medical equipment provider reported $0.26 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.06) by $0.32. BioLife Solutions had a negative net margin of 38.98% and a negative return on equity of 6.61%. The firm had revenue of $22.71 million during the quarter, compared to the consensus estimate of $21.73 million. During the same period in the prior year, the firm earned ($0.21) EPS. On average, research analysts expect that BioLife Solutions, Inc. will post -0.3 EPS for the current year.

Institutional Trading of BioLife Solutions

A number of large investors have recently bought and sold shares of the company. Steward Partners Investment Advisory LLC purchased a new position in shares of BioLife Solutions during the 4th quarter valued at $26,000. Mark Sheptoff Financial Planning LLC bought a new stake in BioLife Solutions in the 3rd quarter valued at about $28,000. Point72 Asia Singapore Pte. Ltd. purchased a new stake in BioLife Solutions during the fourth quarter valued at about $31,000. Quest Partners LLC bought a new position in BioLife Solutions during the third quarter worth about $57,000. Finally, 1620 Investment Advisors Inc. increased its stake in shares of BioLife Solutions by 41.7% in the fourth quarter. 1620 Investment Advisors Inc. now owns 2,295 shares of the medical equipment provider’s stock worth $60,000 after purchasing an additional 675 shares in the last quarter. 93.24% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

BLFS has been the topic of several recent analyst reports. HC Wainwright raised their price objective on BioLife Solutions from $27.00 to $30.00 and gave the company a “buy” rating in a research note on Thursday, March 6th. Benchmark reissued a “buy” rating and set a $30.00 price target on shares of BioLife Solutions in a research report on Thursday, December 19th. KeyCorp upped their price objective on shares of BioLife Solutions from $30.00 to $33.00 and gave the stock an “overweight” rating in a research report on Friday, December 13th. Finally, Northland Securities increased their price objective on shares of BioLife Solutions from $28.00 to $31.00 and gave the company an “outperform” rating in a research note on Wednesday, January 8th. One investment analyst has rated the stock with a sell rating and seven have issued a buy rating to the company. Based on data from MarketBeat, BioLife Solutions has a consensus rating of “Moderate Buy” and an average price target of $29.86.

BioLife Solutions Company Profile

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.